Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GastroLap: Lapatinib vs Lapatinib + Capecitabine in Her2+ Gastro-Esophageal Cancer
NCT01145404Phase 2Terminated
- Sponsor
- National Center for Tumor Diseases
- Start
- Jun 2010
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in gastric cancer (GC), esophageal cancer, gastroesophageal junction adenocarcinoma, sponsored by National Center for Tumor Diseases. Started Jun 2010; status: terminated.
02
Drugs
lapatinib
03
Conditions
gastric cancer (GC)esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01145404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01145404.